MX2016007748A - Composiciones y métodos para tratar, prevenir y diagnosticar cáncer y otros trastornos proliferativos. - Google Patents

Composiciones y métodos para tratar, prevenir y diagnosticar cáncer y otros trastornos proliferativos.

Info

Publication number: MX2016007748A
Authority: MX; Mexico
Prior art keywords: methods; compositions; benzylpropionamide; dioxol; benzo
Prior art date: 2013-12-13

Application number

MX2016007748A

Other languages

English (en)

Spanish (es)

Inventor

A Garland William

Chaudhary Jaideep

STOLLER Glen

Original Assignee

Angiogenex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-13

Filing date

2014-12-14

Publication date

2017-07-28

2014-12-14 Application filed by Angiogenex Inc filed Critical Angiogenex Inc

2017-07-28 Publication of MX2016007748A publication Critical patent/MX2016007748A/es

Links

206010028980 Neoplasm Diseases 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 4
201000011510 cancer Diseases 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
230000002062 proliferating effect Effects 0.000 title 1
SRADCMOCDMFMPS-UHFFFAOYSA-N n-[3-(1,3-benzodioxol-5-yl)-3-(2-methoxyphenyl)propyl]-n-benzylpropanamide Chemical compound C=1C=CC=CC=1CN(C(=O)CC)CCC(C=1C=C2OCOC2=CC=1)C1=CC=CC=C1OC SRADCMOCDMFMPS-UHFFFAOYSA-N 0.000 abstract 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
206010027476 Metastases Diseases 0.000 abstract 1
206010029113 Neovascularisation Diseases 0.000 abstract 1
206010064930 age-related macular degeneration Diseases 0.000 abstract 1
230000002491 angiogenic effect Effects 0.000 abstract 1
238000011394 anticancer treatment Methods 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
230000003463 hyperproliferative effect Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
208000002780 macular degeneration Diseases 0.000 abstract 1
230000009401 metastasis Effects 0.000 abstract 1
206010061289 metastatic neoplasm Diseases 0.000 abstract 1
230000001717 pathogenic effect Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000005855 radiation Effects 0.000 abstract 1
238000001959 radiotherapy Methods 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
230000006439 vascular pathology Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MX2016007748A 2013-12-13 2014-12-14 Composiciones y métodos para tratar, prevenir y diagnosticar cáncer y otros trastornos proliferativos. MX2016007748A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361916116P	2013-12-13	2013-12-13
US201461965776P	2014-02-06	2014-02-06
PCT/US2014/070221 WO2015089495A2 (en)	2013-12-13	2014-12-14	Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders

Publications (1)

Publication Number	Publication Date
MX2016007748A true MX2016007748A (es)	2017-07-28

Family

ID=53371974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2016007748A MX2016007748A (es)	2013-12-13	2014-12-14	Composiciones y métodos para tratar, prevenir y diagnosticar cáncer y otros trastornos proliferativos.

Country Status (6)

Country	Link
EP (1)	EP3079680A4 (de)
JP (2)	JP2017506257A (de)
CN (1)	CN107847470A (de)
AU (1)	AU2014361814A1 (de)
MX (1)	MX2016007748A (de)
WO (1)	WO2015089495A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11304976B2 (en)	2015-02-18	2022-04-19	Enlivex Therapeutics Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) *	2015-02-18	2021-05-11	Enlivex Therapeutics Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
IL287500B2 (en)	2015-04-21	2023-12-01	Enlivex Therapeutics Rdo Ltd	Therapeutic pooled blood apoptotic cell preparations and uses thereof
CA3014885A1 (en)	2016-02-18	2017-08-24	Enlivex Therapeutics Ltd.	Combination immune therapy and cytokine control therapy for cancer treatment
LU100900B1 (de) *	2018-08-10	2020-02-17	Thomas Melchior Homann	Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen
EP3760614B8 (de) *	2019-07-02	2022-04-27	Universität Heidelberg	Chemische inhibitoren von id-proteinen zur behandlung von krebs und anderen erkrankungen
JP2022550589A (ja) *	2019-10-01	2022-12-02	メモリアルスローンケタリングキャンサーセンター	Ｉｄタンパク質の小分子阻害剤
CN113627763B (zh) *	2021-07-30	2023-12-01	厦门大学	一种风险量化评估模型建立方法
CN114480490A (zh) *	2021-12-31	2022-05-13	四川省医学科学院·四川省人民医院	一种构建视网膜新生血管性疾病动物模型的方法
CN115487358B (zh) *	2022-08-05	2023-05-30	核工业四一六医院	一种用于软骨组织修复的凝胶复合支架及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8138356B2 (en) *	2007-10-16	2012-03-20	Angiogeney, Inc.	Chemical inhibitors of inhibitors of differentiation
US20130171158A1 (en) *	2010-06-30	2013-07-04	Garvan Institute Of Medical Research	Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1
US9745288B2 (en) *	2011-08-16	2017-08-29	Indiana University Research And Technology Corporation	Compounds and methods for treating cancer by inhibiting the urokinase receptor

2014
- 2014-12-14 EP EP14870415.8A patent/EP3079680A4/de not_active Withdrawn
- 2014-12-14 AU AU2014361814A patent/AU2014361814A1/en not_active Abandoned
- 2014-12-14 WO PCT/US2014/070221 patent/WO2015089495A2/en not_active Ceased
- 2014-12-14 CN CN201480075495.2A patent/CN107847470A/zh active Pending
- 2014-12-14 JP JP2016558543A patent/JP2017506257A/ja active Pending
- 2014-12-14 MX MX2016007748A patent/MX2016007748A/es unknown
2019
- 2019-09-06 JP JP2019162598A patent/JP2019203028A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CN107847470A (zh)	2018-03-27
JP2017506257A (ja)	2017-03-02
JP2019203028A (ja)	2019-11-28
WO2015089495A2 (en)	2015-06-18
AU2014361814A1 (en)	2016-07-28
EP3079680A4 (de)	2017-11-22
WO2015089495A3 (en)	2015-11-12
EP3079680A2 (de)	2016-10-19

Similar Documents

Publication	Publication Date	Title
WO2015089495A3 (en)	2015-11-12	Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders
PH12019500521A1 (en)	2019-05-27	Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
SG10201808053XA (en)	2018-10-30	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
EA201391416A1 (ru)	2014-04-30	Новые соединения в качестве модуляторов протеинкиназ
MX2017016134A (es)	2018-08-15	Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
PH12018500532A1 (en)	2018-08-29	8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
WO2017096309A8 (en)	2018-06-14	Methods of treatment of malignancies
EA201790267A1 (ru)	2017-10-31	Новые модуляторы киназ
PH12015501370B1 (en)	2015-09-02	Compounds and methods for kinase modulation, and indications therefor
EA201691151A1 (ru)	2017-01-30	Соединения для лечения пациентов с ros1-мутантными раковыми клетками
UA116774C2 (uk)	2018-05-10	Інгібітори серин/треонінкінази
EA201291098A1 (ru)	2013-09-30	Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
CL2012000592A1 (es)	2012-08-03	Compuestos derivados de fenoxi o fenil-tieno[3,2-b]piridina, inhibidores de tirosina quinasas; composicion farmaceutica; y su uso en el tratamiento de cancer colorrectal, de pulmon, hematologico, de higado, mama, en retinopatia diabetica, degeneracion macular, glaucoma, psoriasis, diabetes, enfermedades neurodegenerativas, entre otras.
MX2014013090A (es)	2014-12-08	Derivados de pirrolotriazinona.
EA201692100A1 (ru)	2017-02-28	Новые антитела против rnf43 и способы их применения
EA201491520A1 (ru)	2015-03-31	НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ C-met ПРОТЕИНКИНАЗ
MX362939B (es)	2019-02-27	Derivados de (aza-)isoquinolinona.
MX349550B (es)	2017-08-02	1,7-diazacarbazoles y metodos de uso.
EA201790446A1 (ru)	2017-07-31	Цитотоксические бензодиазепиновые производные
EA201890449A1 (ru)	2018-10-31	Фумагиллиновые гетероциклические соединения и способы их получения и применения
MX357888B (es)	2018-07-27	Sales basicas de adicion de nitroxolina y usos de las mismas.
AU2013260056A8 (en)	2015-01-15	Compounds with TRPV4 activity, compositions and associated methods thereof
PH12018502360A1 (en)	2019-03-25	2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
MX2016004212A (es)	2016-07-11	Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
EA201690302A1 (ru)	2016-06-30	Композиции для местного применения для лечения избыточного потоотделения и способы их применения